

MA9665P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED  
CENTRAL FAX CENTER**

**MAY 01 2007**

First Inventor: Kevin A. Thomas

Serial No.: 10/762,204

Filed: January 20, 2004


For: **RESORBABLE RADIOPAQUE  
MARKERS AND RELATED  
MEDICAL IMPLANTS**

Examiner: Hagopian, Casey Shea

Group Art Unit: 1615

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING OR TRANSMISSION**  
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to: Commissioner for Patents at fax number (571) 273-8300 on May 1, 2007.

  
Kenton R. Mullins, Reg. No. 36,331

**TRANSMITTAL**


Dear Sir:

Submitted herewith are:

- (1) Amendment; and
- (2) Deposit Account Authorization: The Commissioner is hereby authorized to charge any needed fees to deposit account 50-1600.

Respectfully submitted,

Dated: May 1, 2007

  
Kenton R. Mullins  
Attorney for Applicants  
Registration No. 36,331

STOUT, UXA, BUYAN & MULLINS, LLP  
4 Venture, Suite 300  
Irvine, CA 92618  
Tel: 949-450-1750  
Fax: 949-450-1764

MA9665P

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****RECEIVED  
CENTRAL FAX CENTER****MAY 01 2007**

First Inventor: Kevin A. Thomas

Serial No.: 10/762,204

Examiner: Hagopian, Casey Shea

Filed: January 20, 2004

Group Art Unit: 1615

For: **RESORBABLE RADIOPAQUE  
MARKERS AND RELATED  
MEDICAL IMPLANTS**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**AMENDMENT**

Dear Sir:

This is in response to the March 15, 2007 Office Action issued by the United States Patent and Trademark Office regarding the above-identified application. A response to the Office Action is due three months from the mailing date thereof. Accordingly, this Amendment is being timely filed. Please amend the subject application as follows:

**Amendments to the Specification** are reflected on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 4 of this paper.

**Remarks/Arguments** begin on page 11 of this paper.